Quince Therapeutics Reports Q2 2025 Financial Results

Quince Therapeutics ( (QNCX) ) has released its Q2 earnings. Here is a breakdown of the information Quince Therapeutics presented to its investors.

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on leveraging a patient’s own biology to treat rare diseases, with a primary emphasis on developing innovative therapies for conditions like Ataxia-Telangiectasia (A-T). In its latest earnings report, Quince Therapeutics highlighted significant progress in its clinical development pipeline, including the completion of enrollment in the pivotal Phase 3 NEAT clinical trial for its lead asset, eDSP, and a strategic partnership with Option Care Health to support the commercial launch of eDSP in the U.S. The company also reported a strengthened financial position with a cash runway expected to support operations through the second quarter of 2026. Key financial metrics from the second quarter of 2025 include a net loss of $16.1 million, research and development expenses of $6.6 million, and general and administrative expenses of $3.3 million. Quince’s strategic initiatives, including a new financing round and the finalization of Phase 2 study designs for Duchenne muscular dystrophy, underscore its commitment to advancing its therapeutic pipeline. Looking ahead, Quince Therapeutics remains focused on delivering topline results from the NEAT trial in early 2026 and potentially submitting a New Drug Application later that year, positioning itself for future growth and development in the biotechnology sector.